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ABSTRACT
Mesenchymal stem cell commitment to an osteoprogenitor lineage requires the activity of Runx2, a molecule implicated in the
etiopathology of multiple congenital craniofacial anomalies. Through promoter analyses, we have recently identified a new direct
transcriptional target of Runx2, Nell-1, a craniosynostosis (CS)–associated molecule with potent osteogenic properties. This study
investigated the mechanistic and functional relationship between Nell-1 and Runx2 in regulating osteoblast differentiation. The results
showed that spatiotemporal distribution and expression levels of Nell-1 correlated closely with those of endogenous Runx2 during
craniofacial development. Phenotypically, cross-mating Nell-1 overexpression transgenic (CMV-Nell-1) mice with Runx2 haploinsufficient
(Runx2
þ/ ) mice partially rescued the calvarial defects in the cleidocranial dysplasia (CCD)–like phenotype of Runx2
þ/  mice, whereas
Nell-1protein induced mineralization andbone formation inRunx2
þ/  but not Runx2
 /  calvarial explants. Runx2-mediated osteoblastic
gene expression and/or mineralization was severely reduced by Nell-1 siRNA oligos transfection into Runx2
þ/þ newborn mouse calvarial
cells (NMCCs) or in N-ethyl-N-nitrosourea (ENU)–induced Nell-1
 /  NMCCs. Meanwhile, Nell-1 overexpression partially rescued
osteoblastic gene expression but not mineralization in Runx2 null (Runx2
 / ) NMCCs. Mechanistically, irrespective of Runx2 genotype,
Nell-1 signaling activates ERK1/2 and JNK1 mitogen-activated protein kinase (MAPK) pathways in NMCCs and enhances Runx2
phosphorylation and activity when Runx2 is present. Collectively, these data demonstrate that Nell-1 is a critical downstream Runx2
functional mediator insofar as Runx2-regulated Nell-1 promotes osteoblastic differentiation through, in part, activation of MAPK and
enhanced phosphorylation of Runx2, and Runx2 activity is significantly reduced when Nell-1 is blocked or absent.  2011 American
Society for Bone and Mineral Research.
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Introduction
C
ommitment of undifferentiated mesenchymal stem cells to
an osteoprogenitor lineage is first marked by expression
of runt-related transcription factor 2 (Runx2; also known as
Pebp2aA/Cbfa1/Aml3).
(1,2) Runx2 is essential for osteoblast
formation and function because it is expressed by all osteoblasts
irrespective of embryonic origin or mode of ossification.
(3) Runx2
null mutant mice completely lack mineralized bone formation,
whereas heterozygous Runx2 loss-of-function mice manifest a
phenotype similar to cleidocranial dysplasia (CCD) in humans,
consisting of clavicular hypoplasia, delayed development and
ossification of cranial bones causing open anterior and posterior
fontanelles, smaller parietal and interparietal cranial bones, and
multiple wormian bones (small bones in the sutures).
(4,5) Since
Runx2 is a transcription factor, it undoubtedly exerts its critical
osteogenic effects in part through downstream functional
mediators.
(6) However, knockout models of many osteoblastic
genes containing the consensus RUNX2 binding site osteoblast-
specific binding elements 2 (OSE2), such as a1 type I collagen,
(7)
bone sialoprotein,
(8) osteopontin,
(9) and osteocalcin,
(10) in mice
have not yielded significant defects similar to Runx2 deficiency.
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777Our data indicates that Nell-1 may be a key player in addition to
Osx, another critical transcriptional factor for osteoblasts, in the
Runx2 network regulating osteoblastic differentiation.
(11–13)
NELL-1, a secreted protein strongly expressed in neural tissues
and containing epidermal growth factor (EGF)–like domains
(Nel)–like protein type 1, was detected originally to be
upregulated in pathologically fusing and fused sutures in
nonsyndromic unilateral coronal synostosis (UCS) patients.
(14)
Nell-1-overexpressing mice (CMV-Nell-1) exhibit craniosynostosis
(CS)–like phenotypes that ranged from simple to compound
synostoses.
(12) Through promoter analyses, we have established
NELL-1 as a direct target of RUNX2, the master gene of
osteochondrogenic differentiation.
(6,15) The restoration of Nell-1
mRNA expression after Runx2 transfection into Runx2
 /  cells
indirectly confirms the existence of functional OSE2 binding sites
in mouse Nell-1 promoter and further supports in silico analysis
findings of NELL-1 transcriptional regulation by RUNX2.
(15)
Furthermore, ENU-induced Nell-1-deficient mice display similar
CCD-like calvarial phenotypesas Runx2
þ/  miceinaddition torib
cageandvertebralabnormalities.
(16)Thefact thatRUNX2directly
promotes NELL-1 transcripts and ENU Nell-1-deficient mice
exhibit a similar CCD-like phenotype as Runx2
þ/  mice suggests
that NELL-1 may mediate a significant subset of downstream
RUNX2 functions during osteoblastic differentiation in vivo.
The Nell-1 molecule itself is highly conserved across species.
Rat and human Nell-1 proteins share a93% predicted amino acid
homology
(14) and contain several conserved motifs.
(17) More
important, Nell-1 has revealed its osteoinductive potency by
promoting bone regeneration in multiple animal models.
(18–20)
To better delineate the functional relationship between Runx2
and Nell-1 during skeletal development, we have used Runx2-
deficient as well as Nell-1-deficient and -overexpressing mice
models in this study. Because of the obvious calvarial
abnormalities in both Nell-1-overexpressing and Nell-1-deficient
mice, as well as the original identification of NELL-1 upregulation
in human UCS patients, we have focused our present osteoblast
differentiation studies on intramembranous bone development,
although Runx2 is also indispensable for normal chondrocyte
hypertrophy and maturation.
(21,22) Collectively, our data confirm
for the first time that Nell-1 supports continued osteoblastic
differentiation and function in osteoblastic lineage cells during
calvarial development and that Nell-1 is a key functional
mediator of Runx2 osteogenic activity.
Materials and Methods
Generation of Runx2-deficient plus Nell-1 transgenic mice
Runx2 heterozygous deficient mice (Runx2
þ/ )
(4) were mated
with Nell-1-overexpressing mice (CMV-Nell-1)
(12) to generate
Runx2
þ/ /CMV-Nell-1 mice and Runx2
 / /CMV-Nell-1 mice.
Mouse genotypes were determined by PCR, and expression
levels of Nell-1 and Runx2 were monitored using RT-PCR and
were further verified by immunohistochemistry. Mouse embryos
were collected from mating among wild-type mice with vaginal
plugs defined as E0.5 days postcoitum (dpc). Table 1 lists the
total number of animals used for skeletal staining, micro–
computed tomography (mCT), and histology. Animals were
housed and experiments were performed in accordance with
guidelines of the Chancellor’s Animal Research Committee of the
Office for Protection of Research Subjects at the University of
California Los Angeles.
Ex vivo calvarial organ culture
Calvarial vaults of newborn Runx2
þ/  mice were harvested and
placed in serum-free BGJb (Biggers, Gwatkin, Judah) medium
with L-glutamine and supplemented with 100 unit/mL of
penicillin, 100mg/mL of streptomycin, 2.5mg/mL of amphoter-
icin B, 100mg/mL of L-ascorbic acid, and 10mM glyceropho-
sphate. Recombinant Nell-1 (rNell-1) protein (Katayama
Chemical, Ltd., Osaka, Japan) at 100ng/mL was added beginning
on day 1 [plus rNell-1 (n¼8) or minus rNell-1 (n¼5)]. On day 4,
calcein was added to the culture medium at 2mg/mL, and the
explants were maintained for a total of 9 days before harvesting
for gross and histologic analysis of tissue ossification. The calcein
deposition on explants was observed with an Olympus SZX12
fluorescent microscope (Melville, NY, USA), and the relative
intensity of green fluorescence representing the degree of
mineralization on whole explanted calvaria as well as defined
coronal and sagittal suture areas was quantified using Image Pro
Plus (Bethesda, MD, USA). The methyl methacrylate–embedded
sections were analyzed under an Olympus BX51 fluorescent
microscope.
Skeletal and histologic analysis
Newborn mice with the genotypes described in Table 1 were
euthanized with an overdose of phenobarbital, skinned and
eviscerated, and then fixed in 95% ethanol for 24hours at room
temperature. Standard skeletal staining was performed using
Table 1. Summary of Animals Used for Detailed Analysis
Genotype
Total
no. of
animals
No. used for
skeletal analyses
No.
used for
histology
No. of
animals
‘‘rescued’’
from
Runx2
deficiency
a
No.
used for
staining
No.
used for
mCT
Runx2
þ/þ/
CMV-Nell-1 12 4 3 5 Not
applicable
WT 15 2 3 10 Not
applicable
Runx2
R/ /
CMV-Nell-1 27 15 7 5 16 of 22
WT 35 20 5 10 Not
applicable
Runx2
 / /
CMV-Nell-1 83 1 40 o f 4
WT 9 5 1 3 Not
applicable
Total 106 49 20 37
aDetermination of ‘‘rescue’’ status was based on skeletal staining and
mCT analysis.
778 Journal of Bone and Mineral Research ZHANG ET AL.alcian blue for negatively charged proteoglycans and alizarin red
for calcium to provide gross distinction between cartilage and
mineralized tissue, respectively. For histology, tissues were fixed
in 4% paraformaldehyde, embedded in paraffin, and stained
withhematoxylinandeosin(H&E).Skeletalandhistologicimages
were acquired using a MicroFire digital camera with Picture-
Frame software (Optronics, Goleta, CA, USA) attached to
Olympus SZX12 and BX51 microscopes.
High-resolution mCT analysis
High-resolution mCT using 9- to 20-mm resolution technology
from mCT40 (Scanco USA, Wayne, PA, USA) was performed as
described previously.
(18) mCT data were collected at 50 kVp and
160mA and reconstructed using the cone-beam algorithm
supplied with the mCT scanner by Scanco. A threshold of 130 for
3D reconstruction of newborn mouse heads was determined
empirically by evaluating skeletal image of newborn wild-type
mouse heads with serial thresholds to choose the one where no
soft tissue was detected. In addition, CT-based morphometric
analyses were performed on the size of the anterior fontanel, the
closest distance of the sagittal suture, and the average thickness
of parietal bone plates on the same plane in each group
includingRunx2
þ/þ (n¼3), Runx2
þ/  (n¼5), andRunx2
þ/ /CMV-
Nell-1 (n¼7) newborn mice. Data are presented as the
mean SD and analyzed with a two-tailed Student’s t test, with
p .05 considered significant.
Immunohistochemistry
Whole-head samples from E14.5, E16.5, E18.5, and newborn mice
were fixed in 4% paraformaldehyde and then processed for
paraffin embedding. Paraffin-embedded sections were used for
immunohistochemistry employing a previously described pro-
tocol.
(12) Polyclonal rabbit IgG of anti-mouse Nell-1 antibodies
were synthesized against an 11-amino-acid peptide, and the
specificity of the affinity-purified antibody was further confirmed
by Western blot using rNell-1. All other commercially available
antibodies, including anti-Runx2, anti-osteocalcin (Ocn), and
anti-osteopotin (Opn), were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). ABC reagent was from Vector Lab
(Burlingame, CA, USA), and Alex 594–streptavidin was from
Invitrogen (Carlsbad, CA, USA). Negative controls for each
antibody were included and performed accordingly with the
absence of primary antibody.
Isolation and culture of NMCCs
Isolation of Runx2
 /  or ENU-induced Nell-1-deficient
(16) new-
born mouse calvarial cells (NMCCs; n¼5) as well as their
corresponding wild-type (n¼10) or heterozygous NMCCs
(n¼10) was conducted within 2hours of delivery of mice, as
reported previously.
(15) The NMCCs were cultured in a minimum
essential medium (a-MEM) supplemented with 10% fetal bovine
serum (Life Technologies, Inc., Grand Island, NY, USA), 100 units/
mL of penicillin, and 100mg/mL of streptomycin. Cell expansion
was limited to three passages, and the genotype of isolated
NMCCs was further confirmed by PCR or RT-PCR and
immunocytochemistry. NMCCs at third passage were used in
all experiments.
Real-time RT-PCR
TaqMan primer probe sets for Alp, Opn, Ocn, Nell-1, Runx2,a n d
glyceraldehyde-3-phosphate dehydrogenase (Gapdh)w e r ep u r -
chased (Applied Biosystems, Inc., Foster City, CA, USA) and
analyzed using an ABI Prism 7300 real-time reverse-transcriptase
(RT) PCR system (Applied Biosystems) as described previously.
(23)
Relative gene expression profiles were calculated using the
comparative quantification formula as 2
 DDCt based on the
evaluation of similar dynamic ranges for RT-PCR efficiency of both
Gapdh and the target genes. All data are representative of three
experimental sets of cells or three mice tissue specimens with
duplicate PCR running and are presented as the fold difference. In
addition, the Northern blot hybridization and reduced-cycle RT-
PCR also were used for the detection of endogenous levels of
Runx2, Nell-1, Ocn, Osx, Dlx5, and Msx2 in whole-head tissues of
mice with different genotypes, as described previously.
(13) PCR
primer sequences are available on request.
Western blot detection of MAPK pathways activation
NMCCs were synchronized for 18hours in 0.1% fetal bovine
surum (FBS) growth medium before being stimulated with
100ng/mL of rNell-1 for the indicated times. The cells were lysed
in radioimmunoprecipitation assay (RIPA) buffer supplemented
with inhibitors of proteinase and phosphatase (Invitrogen) and
underwent Western blot analysis with antibodies against total
and phosphorylated ERK, JNK and p38 (Santa Cruz Biotechnol-
ogy) using previously reported protocols.
(13)
Immunoprecipitation for Runx2 phosphorylation study
NMCCsweresynchronizedasdescribedearlierandpreincubated
for1hourwiththreeMAPKinhibitorsat25mMSP600125forJNK,
50mM PD98059 for ERK, and 10mM SB203580 for p38 or equal
volume of DMSO vehicle in 0.1% FBS growth medium before
being stimulated with 100ng/mL of rNell-1 for 1 hour.
Immunoprecipitation was done by adding 2mg of anti-Runx2
(Abcam, Cambridge, MA, USA) to 500mL of cell lysate and
incubating for 1 hour at 48C, followed by mixing with 50mLo f
protein G sepharose. The immunoprecipitation products were
probed with anti-Runx2 and anti-pSer (Santa Cruz Biotechnol-
ogy) for detecting Runx2 phosphorylation status.
Reporter assay for transactivation analysis
The reporter assay was done by cotransfection of plasmids of
6OSE2 plus Renilla control with either Runx2 expression plasmid
pcDNA-Runx2 or empty-vector pcDNA3.1 into Runx2
þ/  and
Runx2
 /  NMCCs using Lipofectamin 2000 (Invitrogen). Then
100ng/mL or higher at 800 and 1600ng/mL of rNell-1 and equal
volumes of PBS as control were added to medium 24hours after
transfection, and the medium was incubated for another
24hours before collecting cell lysate for luciferase assay using
a dual luciferase detection kit (Promega, San Luis Obispo, CA,
USA) as described previously.
(15)
Adenoviral transduction with NMCCs
NMCCs at 80% confluence were transduced with AdNell-1,
AdLacZ,o rA d Runx2 at a multiplicity of infection (MOI) of 50
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previously.
(13) Alkaline phosphatase activity and the expression
of Nell-1, Alp, Opn, and Ocn and/or mineralization were analyzed
at the indicated time points.
Transfection of Nell-1 siRNA into NMCCs
Mouse Nell-1 siRNA oligos were designed and synthesized by
Qiagen with the HiPerformance Design Alogrithm based on the
sequences of mouse Nell-1 (Gene Accession No. AK046127). The
specific target sequence was as follows: CAGGTGTGGATTCTGA-
GAGAA. RNAifect reagent and unrelated negative control siRNA
(Qiagen) were used for the transfection of siRNA into NMCCs
according to the manufacturer’s instructions. Briefly, NMCCs
were seeded at 5 10
4/cm
2 into 24-well plates and allowed to
reach 80% confluence the following day for siRNA transfection.
Then 50ng of siRNA oligos per well was mixed with the Perfect
reagent at a ratio of 1:3 and incubated for 10minutes at room
temperature. The blocking efficacy for the expression of mouse
Nell-1 mRNA and protein was measured at 48 and 72hours after
transfection with RT-PCR and Western blot analysis with Nell-1-
specific antibody.
(13) The transfection efficiency and blocking
specificity of Nell-1 siRNA oligos into these cells was monitored
by introducing unrelated siRNA oligos labeled with fluorescein
using the same strategy. For some groups, the transfection of
mouse Nell-1 siRNA oligos was followed by the transduction
of AdRunx2
(24) into the same cells 24hours later. Seventy-two
hours after seeding, cells were switched to differentiation
medium containing 50mg/mL of ascorbic acid and 10mM
glycerol phosphate. The Western blotforNell-1, real-timePCR for
Nell-1, Runx2, Alp, Opn, and Ocn mRNA, and von Kossa staining
were carried out accordingly.
ALP and mineralization assays
Alkaline phosphatase (ALP) staining assay was carried out with
the Leukocytes ALP Staining Kit (86R-1KT, Sigma, St Louis, MO,
USA) as described previously.
(13) Quantitative ALP activity was
assayed with cell lysate and ALP Buffer Solution (Sigma) and
phosphatase substrate capsule (Sigma), as reported pre-
viously.
(20) All measurements were read in triplicate, and the
ALP activity was normalized to corresponding protein quanti-
fications before making relative fold determination against
nontransduced control. The data are presented as the
mean SD with a t-test significance of p .05. The von Kossa
and alizarin red staining (ARS)/quantification assays were
performed as described previously.
(12,20)
Cell proliferation and apoptosis analysis
To determine nonspecific toxicity of MAPK inhibitors, NMCCs
were seeded at 2 10
3 cells/well in 96-well plates in the
presence of MAPK inhibitors or DMSO vehicle for proliferation
study by the MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide] method (Promega). The optical density
(OD) values at 490nm were plotted for relative comparison
among different treatment groups. For apoptosis analysis,
NMCCs were plated in 6-well culture dishes and treated with
MAPK inhibitors at the same concentration used for the Runx2
phosphorylation study for 6 days in osteoblastic differentiation
medium. The Annexin V and propidium iodide (PI) Kit
(Pharmingen, San Diego, CA, USA) was used for staining cells,
followedbyflowcytometricanalysis.Thepercentageofearlyand
late apoptotic cells was calculated and presented.
Results
Spatiotemporal expression of Nell-1 and Runx2 during
mouse craniofacial bone development
To determine the spatiotemporal expression pattern of Runx2
and Nell-1 during craniofacial bone formation, immunohisto-
chemistry was performed on whole-head sections of E14.5,
E16.5, and E18.5 mouse embryos. Consistent with its critical role
in osteoblastogenesis, Runx2 expression was present in every
axial, appendicular, and cranial skeletal anlage at E12.5,
(3)
although mineralization of craniofacial bones occurs later, at
E14.5. In E14.5 mice, significantly high levels of Nell-1 expression
closely approximated and overlapped with Runx2 expression in
temporal and parietal bone plates (Fig. 1A). Osteoblast cells
along the temporal bone plates with typical nucleus staining for
Runx2 (Fig. 1A, lower panel) also stained strongly for Nell-1 in the
cytoplasm and nucleus (Fig. 1A, upper panel). In E16.5 mice, the
spatial distribution of Nell-1 expression expanded to cover bone-
forming areas of the cranial vault, base, and mandible (Fig. 1B).
High-intensity Nell-1-positive cellslocalizedprimarily toossifying
membranous bone-forming regions in the cranial base as well as
nonossifying regions such as the dura mater (Fig. 1B, upper
panel). Interestingly, in E18.5 mice, Runx2 expression was
relatively low in calvarial bone and dura mater when compared
with Nell-1 expression (Fig. 1C). To complement the immuno-
histochemistry data, relative Runx2 and Nell-1 mRNA levels in
isolated E14.5, E16.5, and E18.5 calvarial bones were determined
by real-time RT-PCR. Nell-1 expression closely paralleled Runx2
mRNA expression with a significant decline in levels from E14.5
to E16.5 (Fig. 1D, upper panel). Overall, the craniofacial
localization and expression pattern of Nell-1 followed that of
Runx2. The close temporal and spatial overlap in Runx2 and Nell-
1 expression at multiple embryonic stages suggests a possible
regulatory relationship between Runx2 and Nell-1 during mouse
craniofacial development.
To determine if the observed similarity in Runx2 and Nell-1
expression patterns in calvarial bones also were present in long
bones, neonatal calvaria and long bone (femur and tibia) RNA
were analyzed by real-time RT-PCR. Results demonstrated that
Runx2 levels in newborn calvarial bone were higher than in
newborn long bone. Relatively high Runx2 levels in calvaria were
associated with high calvarial Nell-1 levels, whereas lower Runx2
levels in long bone were associated with lower Nell-1 levels
(Fig. 1D,lower panel).These datademonstrated closely paralleled
expression patterns for Nell-1 and Runx2 in both calvarial and
long bone tissues, as well as significantly higher Nell-1 and Runx2
RNA levels in calvaria versus long bones during development.
Diminished expression of Nell-1 in craniofacial tissues
with Runx2 deficiency
The preferential expression of Nell-1 and Runx2 in calvaria versus
long bones and their spatiotemporal distribution pattern in
780 Journal of Bone and Mineral Research ZHANG ET AL.craniofacial bones led us to further investigate the relationship
between Runx2 and Nell-1 in the context of Runx2 disruption.
Whole-head tissues from wild-type (Runx2
þ/þ), Runx2
þ/ , and
Runx2
 /  newborn mice were examined for expression of Nell-1
and Ocn by Northern blot (Supplemental Fig. S1A). The highest
expression of an approximately 3.5-kb single transcript of Nell-1
and an approximately 0.7-kb OcnwasreadilydetectedinRunx2
þ/þ
tissue, and only weak signals were observed in Runx2
þ/ ,
whereas both Nell-1 and Ocn were undetectable in all Runx2
 / 
tissues. In addition, the expression levels of Nell-1 and Ocn,a s
well as Runx2 and other genes critical in craniofacial develop-
ment, including Osx, Dlx5, and Msx2, were verified and screened
Fig. 1. Spatiotemporal expression of Runx2 and Nell-1 during mouse craniofacial development. (A) E14.5, (B) E16.5, and (C) E18.5 mice craniofacial tissues
were treated with Nell-1 (upper panel) or Runx2 (lower panel) antibody for immunohistochemistry. Low-magnification (left) and high-magnification (right,
color framed) images demonstrate cellular localization and tissue distribution of Nell-1 and Runx2 in embryos at different stages. Arrows indicate areas of
positive staining. Nuclear localization of Runx2 and prominent cytoplasmic staining of Nell-1 were clearly displayed in osteoblast cells along the temporal
bone plate in E14.5 and E16.5 embryos as well as in osteoblast cells along parietal bone plates in E18.5 embryos. Scale bar: 500mm for low-magnification
and 50mm for high-magnification images in panels A and B; 250mm for low-magnification and 50mm for high-magnification images in panel C.
(D) Graphic depictionof calvarialboneNell-1(red line) andRunx2(blue line) mRNAexpressionduringembryonicdevelopment (top). Bar graph depictionof
significantly higher Nell-1 (in red) and Runx2 (in blue) mRNA expression in calvaria versus long bone in newborn animals (bottom) by real-time RT-PCR.
 p<.05;
  p<.01.
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head tissues used for Northern blot analysis (Fig. 2A). Results
revealedthatthelevelsofRunx2expressioninRunx2
þ/þ,Runx2
þ/ ,
and Runx2
 /  samples correlated very well with the expression
levels of Nell-1, Ocn, and Osx, whereas the levels of Dlx5 and Msx2
were similar in both Runx2
þ/  and Runx2
 /  samples. These
results indicate that Nell-1, Ocn, and Osx gene transactivation is
highly dependent on underlying Runx2 levels.
To specifically correlate Runx2 and Nell-1 expression in bone-
forming tissues, the gene expression levels of Runx2, Nell-1, Ocn,
Opn, and Alp were further analyzed with newborn mouse
calvarial cells (NMCCs) (Fig. 2B) by real-time RT-PCR, and the
protein level of Nell-1 in situ was detected in Runx2
þ/þ and
Runx2
 /  craniofacial tissue sections by immunohistochemistry
(Fig. 2C–H). Nell-1 expression levels in NMCC correlated well with
Runx2 genotypes and mRNA levels of Runx2, Alp, Opn, and Ocn;
the highest Nell-1 levels were present in Runx2
þ/þ cells,
intermediate levels were seen in Runx2
þ/  cells, and there were
barely detectable levels in Runx2
 /  cells. Nell-1 immunohis-
tochemistry on Runx2
þ/þ and Runx2
 /  newborn craniofacial
tissues revealed greatly diminished Nell-1 staining intensity in
Runx2
 /  mice calvarial tissue, dura mater, and mandibular
Fig. 2. Nell-1 mRNA and protein levels in craniofacial tissues of newborn Runx2-deficient mice. (A) Reduced cycle RT-PCR on Runx2, Nell-1, Ocn, Osx, Dlx5,
Msx2, and Gapdh mRNA levels from whole-head tissues of newborn wild-type (WT), Runx2 haploinsufficient (Runx2
þ/ ), or Runx2 null (Runx2
 / ) mice.
(B)Quantitativereal-timeRT-PCRanalysisonRunx2,Nell-1,Alp,Opn,andOcnmRNAlevelsfromNMCCs(newbornmousecalvarialcellsisolatedfrom10WT,
10 Runx2
þ/ , and5 Runx2
 / mice)withWT(yellow),Runx2
þ/  (blue),orRunx2
 / (orange) genotypes.
 p<.05;
  p<.01.(C) Nell-1immunohistochemistry
on coronal sections from WT newborn mouse head at low magnification (scale bar: 500mm) and corresponding high-magnification areas at (D) the
highlightedsagittal suture(upper,black border; scale bar:100mm),temporalbone(lower, red border; scale bar:100mm) and(E) themandible(green border;
scale bar: 50mm). Significant positive Nell-1 staining is evident across the section, and readily identifiable positive cells are seen at the calvarial sagittal
suture(sS),parietalbone(pB),duramater(Dm),andscalp(Sk).Prominentpositivestainingalsowaspresentattheperiosteum(arrows)ofmandibularbone
(mB). ( F) Nell-1 immunohistochemistry on coronal sections from a newborn Runx2
 /  mouse head. Nell-1 protein was undetectable in the Runx2
 / 
mouse head (scale bar: 500mm) in contrast to its WT littermates. Corresponding (G) sagittal suture (upper, black border; scale bar: 100mm), temporal bone
(lower, red border; scale bar: 100mm) and (H) mandible (green border; scale bar: 50mm) areas show distinct absence of bone development and no Nell-1
staining. Nell-1 staining in Runx2
 /  animals was present primarily in skin (G) and a few chondrocytes (H)( arrows) in Meckel’s cartilage (mC).
782 Journal of Bone and Mineral Research ZHANG ET AL.bones compared with wild-type mice (Fig. 2C–H). Collectively,
the close correlation between Nell-1 and Runx2 expression
indicates that Runx2 is an important in vivo regulator of Nell-1
expression and is consistent with our data demonstrating
potentially functional Runx2 binding sites on the Nell-1
promoter.
(15)
Nell-1 partially rescues CCD-like calvarial defects in
Runx2
þ/  mice
Global Nell-1-overexpressing mice using a CMV promoter (CMV-
Nell-1) exhibit phenotypes related to calvarial overgrowth and
premature suture fusion without obvious extracranial abnorm-
alities (despite verification of global Nell-1 transgene expres-
sion).
(12) To determine whether Nell-1 can functionally
compensate for some aspects of Runx2 deficiency (eg, CCD
phenotype), Runx2
þ/  mice were mated to CMV-Nell-1 mice to
generate Runx2
þ/ /CMV-Nell-1 mice. A total of 106 newborn
mice recovered from 14 litters were included in this study
(Table 1). As expected, newborn wild-type mice showed
dramatically different patterns of cranial bone skeletal staining
compared with Runx2
þ/  mice. Consistent with previous reports,
the majority of Runx2
þ/  mice exhibited developmental ano-
malies resembling the CCD phenotype described by Otto and
colleagues (eg, hypoplastic clavicles, wide sutures, and delayed
membranous bone ossification resulting in open anterior and
posterior fontanelles as well as widecranial sutures)
(4) (Fig. 3A, B).
Remarkably, 16 of the 22 Runx2
þ/ /CMV-Nell-1 mice demon-
strated ‘‘rescue’’ of calvarial bone defects associated with the
CCD phenotype on skeletal or mCT analyses (Fig. 3C, D), whereas
Nell-1did notrescue boneformationintheRunx2nullmice(data
not shown). Quantitative mCT data confirmed significant
Fig. 3. Skeletal and histochemical analysis of rescued CCD Runx2
þ/  newborn mice. (A) The skeletal staining (top) and mCT (bottom) of a wild-type mouse
demonstrating typical mineralization borders (dotted light blue line) and the location of the anterior (red asterisk) calvarial fontanel. The coronal sutures
(green arrows) also are highlighted. (B) Runx2
þ/  animal demonstrating widely patent midline sutures and fontanels. Defective mineralization and bone
formation are present in the poorly stained tissue (between yellow and light-blue dotted lines) lateral to the midline calvarial defect. A lucency also can be
seen in the area of the coronal suture (green arrows, top and bottom pictures). (C) Runx2
þ/ /CMV-Nell-1 animal demonstrating significantly increased
calvarial bone formation relative to the Runx2
þ/  animal on skeletal staining and mCT. Note the restoration of bony overlap at the coronal sutures (green
arrows) and decreased anterior fontanel size (red asterisk). Scale bar: 1mm for mCT images. (D) The red line is drawn through the location of parietal bones
(top,upperleftimage)forcross-sectionalanalysis.Cross-sectionalviewwithlabelsd1tod4(top,centerimage).Thelabeld1representssagittalsuturewidth,
whereasd2throughd4are measurement pointsofparietal bonethickness startingfromd2at 0.5-mmintervals.Quantitativeanalysisof theaveragewidth
and thickness are depicted graphically (bottom charts,
 p<.01;
  p<.05; NS¼no significance). (E–G) Immunohistochemistry of Nell-1, Opn, and Ocn as
well as (H) Alp enzymatic histochemistry on calvarial bones. Runx2
þ/ /CMV-Nell-1 tissues demonstrated markedly higher staining intensity (red color) for
Nell-1, Opn, and Ocn (yellow arrows) relative to Runx2
þ/  tissues, whereas Alp activity did not show significant differences. Scale bar: 50mm.
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þ/ /CMV-Nell-1 mice
compared with Runx2
þ/  mice (p<.05; Fig. 3D). Furthermore,
parietal bone thickness in Runx2
þ/ /CMV-Nell-1 mice was
significantly increased relative to Runx2
þ/  mice (p<.01) and
comparable with wild-type (Runx2
þ/þ) bone thickness (Fig. 3D).
In addition, the anterior fontanelle openings in Runx2
þ/ /CMV-
Nell-1 mice were markedly smaller than in Runx2
þ/  mice by
visualization (Fig. 3C). Preliminary analysis of calvaria from P21
mice by mCT also revealed narrower sagittal sutures and increas-
ed intensity of calvarial bones in Runx2
þ/ /CMV-Nell-1 mice
compared with Runx2
þ/  mice (Supplemental Fig. S1B). There
was no rescue of clavicular hypoplasia because no significant
difference was observed in clavicle length or thickness between
Runx2
þ/  and Runx2
þ/ /CMV-Nell-1 mice (data not shown).
Immunohistochemistry clearly demonstrated increased Nell-1,
Opn, and Ocn in calvarial bone plates of the rescued Runx2
þ/ /
CMV-Nell-1 mice (Fig. 3E–G) but not increased Alp (Fig. 3H). These
data show that Nell-1 can functionally compensate for some
aspects of Runx2 deficiency and suggest that Nell-1 is a key
downstream mediator of Runx2’s effects on osteoblastic
differentiation and bone formation.
Nell-1 enhanced mineralization in ex vivo calvarial
explants from Runx2
þ/  mice
Since a global Nell-1 expression model partially rescued the CCD
phenotype in Runx2
þ/  mice, to further confirm that the
Fig. 4.
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attributable to Nell-1 activity in osteoblastic cell lineages,
calvarial explants from Runx2
þ/  and Runx2
 /  newborn mice
were cultured in the presence (Fig. 4A–C, G) or absence (Fig. 4D–
F, H) of recombinant (r)Nell-1 to create an environment without
systemic influences. In general, Runx2
þ/  explants stimulated
with rNell-1 contained (Fig. 4A–C) more mineralization (as
detected by calcein incorporation fluorescence) than explants
cultured in the absence of rNell-1 (Fig. 4D–F). Specifically, rNell-1
stimulated significantly increased calcein uptake at actively
extending osteogenic fronts of parietal bone plates (Fig. 4A).
Histologic sections of sagittal and coronal sutures revealed
markedly increased mineralization accompanied by impending
sagittal suture fusion (Fig. 4B) and actual coronal suture fusion
(Fig. 4C). Normally, wild-type mice sagittal and coronal sutures
are expected to remain patent.
(25) rNell-1 treatment also
increased the thickness and size of parietal bones when
compared with PBS vehicle control (Fig. 4D–F). Meanwhile,
the control calvarias exhibited minimal mineralization within the
sagittal suture mesenchyme (Fig. 4E) and between the over-
lapping frontal and parietal bone plates comprising the coronal
suture (Fig. 4F). Consistent with the lack of Nell-1 rescue of bone
formation in Runx2
 /  mice, Runx2
 /  calvarial explants cultured
with or without rNell-1 did not exhibit any significant differences
in alizarin red staining (Fig. 4G, H). Furthermore, the mineraliza-
tion intensity increased by 46% overall with the presence of
rNell-1 compared with the vehicle group when whole explanted
calvaria were measured (wEx). There was a slightly higher
increase, at 63% and 55%, in defined sagittal and coronal suture
(sS and cS) regions of the samples with rhNell-1 treatment over
vehicle control, respectively (Fig. 4I). Taken together, these ex
vivo studies clearly demonstrated that Nell-1 was sufficient to
promotemineralizationandboneformation(eg,suturefusion)in
Runx2
þ/  mice containing committed preosteoblast cells but
insufficient to promote mineralization in Runx2
 /  mice contain-
ing undifferentiated mesenchymal cells. These data indicate that
Nell-1 is not sufficient to promote bone formation in the absence
of Runx2 and that some level of Runx2-dependent factors or
Runx2 itself is required for Nell-1 to promote full osteoblastic
differentiation.
To investigate the underlying mechanisms of Nell-1 respon-
siveness in Runx2
þ/  backgrounds and lack thereof in Runx2
 / 
backgrounds, the activation of three major MAPK pathways,
including ERK, JNK, and p38, and Runx2 phosphorylation status
were investigated using Runx2
þ/  and/or Runx2
 /  NMCCs.
Currently, it is known that phosphorylation can modulate Runx2
activity, and increased Runx2 phosphorylation has been
observed after rNell-1 stimulation of rat fetal calvarial cells.
(26,27)
Our data indicated that rNell-1 stimulation markedly intensified
phosphorylation of both ERK1/2 and JNK1 starting at 10minutes
in both Runx2
þ/  and Runx2
 /  cells, but phosphorylation was
higher and more sustained in Runx2
þ/  cells than in Runx2
 / 
cells (Fig. 4J). Interestingly, phosphorylated p38 (p-p38) levels
were consistently high and did not change much on Nell-1
stimulation in either Runx2
þ/  or Runx2
 /  cells (Fig. 4J). The
Runx2
þ/þ NMCCs exhibited similar ERK and JNK pathway
phosphorylationpatternsasthatofRunx2
þ/ NMCCsinresponse
to rNell-1 stimulation (Supplemental Fig. S1C and Fig. 4J).
Meanwhile, rNell-1 increased phosphorylated Runx2 levels (WB:
p-Ser) in Runx2
þ/  NMCCs (Fig. 4K). Furthermore, Nell-1
significantly increased the transactivating activity of Runx2
(Fig. 4L). Relative luciferase activity using the 6OSE2 reporter
plasmid (6OSE) was significantly higher in Runx2
þ/  NMCCs
treated with rNell-1 (versus PBS) when cotransfected with empty
vector (pcDNA3.1) and in both Runx2
þ/  and Runx2
 /  NMCCs
when treated with rNell-1 (versus PBS) and cotransfected with
Runx2 expression plasmid (pRunx2). Overall, a dose-dependent
effect on 6OSE activity was observed with increasing rNell-1
application (Supplemental Fig. S1D). These data indicate that
Nell-1 responsiveness in Runx2
þ/  but not Runx2
 /  back-
grounds may result from sustainable and strong activation of
ERK and JNK pathways and enhanced phosphorylation of, in
Fig. 4. Nell-1 protein promotes Runx2
þ/  calvarial explant mineralization and activates MAPK pathways with NMCCs. (A) Runx2
þ/  calvarial explants with
rNell-1stimulationdisplayedintensecalceinfluorescentlabelingattheperipheraledgesofparietalbones(P),coronalsutures(cS),andsagittalsutures(sS),
indicating active mineralization. (B) Coronal section displaying fluorescent incorporation in a sagittal suture (sS) corresponding to the red line in panel A.
rNell-1 induces significant mineralization in sagittal suture mesenchyme and osteogenic fronts of parietal bone (yellow arrows). (C) Coronal section
displaying fluorescent incorporation in a coronal suture corresponding to the yellow line in panel A. Nell-1 induces marked new bone formation with
resulting fusion of the overlapping frontal and parietal bone plates at the coronal suture (yellow arrow). (D) Runx2
þ/  calvarial explants without rNell-1
stimulation revealed reduced mineralization, as represented by green fluorescent staining throughout the entire calvarial vault. (E) Coronal section
displayingfluorescentincorporationinasagittalsuturecorrespondingtotheredlineinpanelD.Reducedsuturalandosteogenicfrontmineralizationwere
observed. (F) Coronal section displaying fluorescent incorporation in a coronal suture corresponding to the yellow line in panel D. A well-separated gap
between the overlapping frontal and parietal bones demonstrating coronal suture patency (yellow arrow). (G) Skeletal staining of Runx2
 /  calvarial
explants (withbrain attached)with rNell-1or(H) without rNell-1did not showany alizarinred stainingexceptfor hyoidbone(Hb).Scalebars: 500mmfor A
andD;5 0mmfor B, C, E, andF; 1mmforGandH.(I) Quantitativemeasurement ofmineralization intensityusingImageProPlusonwholeexplantedcalvaria
(wEx) and the defined sagittal suture (sS) and coronal suture (cS) (top image) revealed significant increase in samples with rNell-1 treatment (bottom
bar graph)(
  p<.01). (J) Three major MAPK pathways, ERK, JNK, and p38, were tested for activation status on rNell-1 stimulation of Runx2
þ/  or Runx2
 / 
NMCCs. rNell-1 stimulation intensified the phosphorylation of both ERK1/2 and JNK1 starting at 10minutes in Runx2
þ/  and Runx2
 /  NMCCs, but
prolonged ERK1/2 and JNK1 phosphorylation was present only in Runx2
þ/  and not Runx2
 /  NMCCs. (K) rNell-1 markedly increased the level of
phosphorylated Runx2 (WB: p-Ser band at top) after 1 hour of stimulation with band-density analysis (graph at bottom). (L) Relative Runx2 activity in both
Runx2
þ/  and Runx2
 /  NMCCs was assessed using a 6OSE2 luciferase reporter construct. Relative luciferase activity was significantly higher in rNell-1-
versus PBS-treated NMCCs when cotransfected with Runx2 expression plasmid (dark blue and dark yellow in pRunx2/6OSE). Higher luciferase activity also
was induced by rNell-1 on Runx2
þ/  calvarial cells when cotransfected with pcDNA3.1 empty vector (dark yellow in pcDNA3.1/6OSE), whereas only
background luciferase activity, similar to that from cells without 6OSE2 transfection (No treatment), was noticed on Runx
 /  calvarial cells when
cotransfected with empty vector (dark blue in pcDNA3.1/6OSE).
 p<.05 versus corresponding PBS group.
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Nell-1 knockdown partially blocked Runx2-induced
osteoblastic differentiation of NMCCs
Having established that Nell-1 is sufficient to promote miner-
alization and bone formation (eg, suture fusion) in partially
deficient Runx2 states (eg, Runx2
þ/ ), the next step was to
determine whether normal Runx2-induced osteoblastic differ-
entiation (eg, Runx2
þ/þ) requires Nell-1. Wild-type (Runx2
þ/þ)
NMCCs express endogenous Nell-1 at relatively low levels, but
Nell-1 expression is rapidly induced on Runx2 stimulation. To
establish whether Nell-1 blockade will inhibit Runx2-mediated
osteogenicdifferentiation,wild-typeNMCCswerepretransfected
with Nell-1 siRNA (siRNA
Nell-1) or unrelated negative control
siRNA 24hours prior to AdRunx2 infection and compared
with AdRunx2 transduction alone and no treatment controls
Fig. 5. Nell-1 is critical for Runx2-induced osteoblastic differentiation in NMCCs. (A) Real-time RT-PCR Nell-1 expression (top bar graph) 48hours after
siRNA
Nell-1 and unrelated negative control siRNA transfection and/or 24hours after AdRunx2 transduction. AdRunx2 significantly increased Nell-1
transcripts in calvarial cells up to 9.5-fold, whereas siRNA
Nell-1 transfection decreased the AdRunx2-mediated Nell-1 response by approximately 3-fold. No-
treatment controlrevealedlow basal Nell-1 expression. In agreement with the real-timeRT-PCR Nell-1 expression data, siRNA
Nell-1 transfectionalso blocked
upregulationofNell-1proteinbyAdRunx272hoursaftertransduction(bottomimageofWesternblot).(B)Real-timeRT-PCR(topbargraph)ofrelativeNell-1,
Runx2, Opn, Ocn, and Alp levels 48hours after siRNA transfection and/or 24hours after AdRunx2 transduction. siRNA
Nell-1 transfection significantly
abrogated AdRunx2-associated upregulation of Nell-1, Opn, and Ocn but not Alp (
 p<.05;
  p<.01). Von Kossa staining (bottom images) of NMCCs on
day 18 showed that siRNA
Nell-1 transfection significantly inhibited mineralization of AdRunx2-transduced calvarial cells (whole-plate image at left and
higher-magnification images at right of each panel). (C)A d Runx2 transduction promoted mineralization (ARS¼alizarin red staining) in wild-type calvarial
cellsbutnotinNell-1
 / calvarialcellsfromENU-inducedNell-1-deficient mice(wholeplate imageattopandhigher-magnificationimageatbottomofeach
panel ).( D) rNell-1 significantly enhanced Runx2 phosphorylation (WB: p-Ser) (top image, first two lanes). All three MAPK inhibitors partially blocked Nell-1-
associated Runx2 phosphorylation and mineralization (ARS) in Runx2
þ/þ NMCCs (lower bar graph).
 p<.05; NS¼no significance.
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confirmed that only siRNA
Nell-1 significantly blocked Runx2-
induced production of Nell-1 transcripts and protein. Quantita-
tively, Nell-1 mRNA was 9.5-fold higher in NMCCs transduced
with AdRunx2 compared with control NMCCs. Up to 70% of the
upregulated Nell-1 mRNA was significantly knocked down using
siRNA
Nell-1 treatment (Fig. 5A). Functionally, siRNA
Nell-1 treatment
significantly decreased Opn and Ocn expression by 80% and
50%, respectively, without significant effects on Alp or Runx2
transcription (p>0.05; Fig. 5B, upper panel). Meanwhile, NMCCs
transduced with AdRunx2 revealed more prominent and thicker
mineralized clusters, as detected by von Kossa staining, whereas
siRNA
Nell-1 addition substantially inhibited mineralization in the
AdRunx2-transduced NMCCs (Fig. 5B, lower panel). Consistent
with the Alp mRNA data in Fig. 5B, Alp activity of NMCCs on days
3, 6, and 9 after transfection with Nell-1 siRNA with or
without AdRunx2 revealed only minor alterations on days 6
and 9 (data not shown).
Notably, the transduction of AdRunx2 enhanced mineraliza-
tion [as assessed by alizarin red staining (ARS)] on wild-type (ie,
Nell-1
þ/þ) calvarial cells but not on Nell-1
 /  calvarial cells
derived from ENU-induced Nell-1-deficient mouse (Fig. 5C),
indicating that Nell-1 is required for Runx2’s function on terminal
osteoblast differentiation and mineralization. In addition, rNell-1
significantly increased phosphorylated Runx2 (WB: p-Ser) in
Runx2
þ/þand Runx2
þ/  NMCCs. Meanwhile, all three MAPK
inhibitors (JNK, p38, and ERK) partially blocked Runx2 phosphor-
ylation and decreased Nell-1-induced mineralization (Fig. 5D).
However, the inhibitors of JNK (SP600125) and ERK (PD90589)
also decreased cell proliferation (Supplemental Fig. S1E) and
increased apoptosis when added alone (Supplemental Fig. S2) in
NMCCs. Thus nonspecific toxic effects from the inhibitors also
may have contributed to the observed suppression of Nell-1-
induced mineralization.
Collectively, these data show that Nell-1 knockdown by
siRNA
Nell-1 or intrinsic Nell-1 deficiency (Nell-1
 /  from ENU-
induced mutation) functionally compromises Runx2-induced
Opn and Ocn expression and ECM mineralization—confirming
that Nell-1 is a significant functional mediator of downstream
Runx2 activity. In addition, the enhanced Runx2 phosphorylation
through activation of MAPK pathways by Nell-1 is one of the
mechanisms underlying the functional relationship between
Runx2 and Nell-1.
Nell-1 partially restored osteoblastic differentiation in
Runx2 null NMCCs
Although Nell-1 overexpression did not restore bone formation
in the Runx2
 / /CMV-Nell-1 mice and rNell-1 did not mineralize
Runx2
 /  calvarial explants, it is of interest to determine whether
Nell-1 can induce osteogenic differentiation in the absence of
Runx2—becauseNell-1expressionwasnotcompletelyabsentin
Runx2-deficient animals (Fig. 2A, F–H). Osteoblastic marker gene
expression, Alp activity, and mineralization were examined in
Runx2
 /  NMCCs transduced with AdNell-1 and AdLacZ. Surpris-
ingly, Alp activity was significantly increased in AdNell-1-
transduced Runx2
 /  NMCCs on day 12 (Fig. 6A, B), and Alp
transcripts were increased over 20-fold on day 9 (Fig. 6C).
Notably, Opn, a slightly later marker of osteoblastic differentia-
tion,alsowasincreasedfourfoldonday9,whereasOcnremained
unchanged (Fig. 6C). These data are distinctly different from
those in Runx2
þ/  animals, where Opn, Ocn, but not Alp, were
significantly upregulated with in vivo Nell-1 compensation
(Fig. 3F–H). Overexpression of Nell-1, however, was insufficient to
induce mineralization in Runx2
 /  NMCCs even after 27 days of
culture, whereas Nell-1-transduced Runx2
þ/þ NMCCs were highly
mineralized (Fig. 6D). Taken together, these results show that
Nell-1 overexpression in Runx2
 /  NMCCs can induce a certain
level of osteogenic differentiation independent of Runx2 (as
evidenced by initial Alp and then Opn expression), but Nell-1
alone is insufficient to promote terminal osteoblastic differentia-
tion (ie, mineralization) in Runx2
 /  NMCCs cells. This accounts
for the inability of Nell-1 to rescue mineralized bone formation in
Runx2
 /  mice.
Discussion
Commitment of undifferentiated mesenchymal stem cells to an
osteoprogenitor lineage is first marked by expression of
Runx2.
(1,2) Furthermore, most described osteoinductive factors
appear to converge mechanistically at Runx2 as well. Examples
include bone morphogenetic proteins (BMP) 2 and 7, insulin-like
growth factor (IGF-1), and transforming growth factor (TGF) b1,
which are known to functionally modulate Runx2.
(1,28–30)
Meanwhile, fibroblast growth factor (FGF) 2 may increase Runx2
activity through a mitogen-activated protein kinase (MAPK)
pathway, whereas parathyroid hormone (PTH) may increase
Runx2 activity through protein kinase A and C (PKA and PKC)
pathways.
(27,31) In addition, Javed and colleagues have demon-
strated recently that RUNX2 is a critical molecular end point for
execution and completion of TGF-b/BMP signaling in osteo-
blasts.
(32) Overall, Runx2 is essential for osteoblast formation and
function because it is expressed by all osteoblasts irrespective of
embryonic origin or mode of ossification.
(3) However, the exact
mechanism by which Runx2 exerts its activity on osteoblasts and
chondrocytes is largely unknown. Except for osterix (Osx),
another transcription factor that is absolutely required for
osteoblast formation,
(11,33) attempts thus far to identify critical
downstreamfunctionalmediatorsofRunx2inmineralizationand
bone formation have not been successful. We previously
established that the human NELL-1 gene is directly regulated
by Runx2
(15) and that Nell-1-deficient mice exhibit severe axial
and appendicular skeletal anomalies
(16)—indicating that Runx2-
regulated Nell-1 is required for normal skeletogenesis. We show
here that Nell-1 is a critical downstream Runx2 functional
mediator.
In this study, we verified on multiple levels that mechan-
istically, Runx2 exerts many of its effects on osteoblasts through
Nell-1. Specifically, (1) temporally and spatially, Nell-1 expression
correlated closely with endogenous Runx2 expression in calvarial
and long bone tissues in wild-type and Runx2-deficient mice, (2)
cross-mating CMV-Nell-1 mice with Runx2
þ/  mice partially
rescued the CCD-like calvarial defects phenotype, (3) rNell-1
protein added to mineralization-defective Runx2
þ/  calvarial
explants induced mineralization and bone formation at sagittal
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JNK1 phosphorylation, which is followed by increased Runx2
phosphorylation and activity in a dose-dependent manner, (5)
Runx2-mediated osteoblastic differentiation and mineralization
was significantly reduced by transfection of Nell-1 siRNA to
Runx2
þ/þ NMCCs and in ENU-mutated Nell-1
 /  NMCCs, and
(6) AdNell-1 partially rescued osteoblastic gene expression but
notmineralizationinnewborncalvarialcellsfromRunx2
 / mice.
Collectively, these data demonstrate that Nell-1 is a critical
downstream Runx2 functional mediator insofar as Runx2-
regulated Nell-1 promotes osteoblastic differentiation through,
in part, activation of MAPK and enhanced phosphorylation of
Runx2and thatRunx2activityissignificantlyreduced when Nell-1
is blocked or absent.
In our previous report, NELL-1 localized to more mature
osteoblasts at the osteogenic front in fusing and newly fused
sutures from UCS patients.
(14) This study confirmed a close
correlation between levels of endogenous Runx2 and Nell-1
expression during development at the tissue level (eg, lower
Nell-1 in long bone versus calvaria) and genotype levels (eg,
higher Nell-1 in Runx2
þ/þ versus Runx2
þ/ ), which suggests that
the multifunctional OSE2 sites on the Nell-1 promoter described
previously
(15) are highly relevant to controlling Nell-1 transcrip-
tion in vivo. The CCD-like calvarial defect phenotype of Nell-1-
deficient mice further indicates that Nell-1 has a critical role in
the Runx2 osteoblastic differentiation pathway.
The importance of Nell-1 as a downstream mediator of Runx2
activity was clearly demonstrated when siRNA inhibition of Nell-1
significantly reduced Runx2-induced mineralization of Runx2
þ/þ
NMCCs as well as Runx2-induced upregulation of Opn and Ocn
but not necessarily Alp. In addition, a significant reduction in
Runx2-induced mineralization also was observed in Nell-1-
deficient NMCCs. These data are consistent with Nell-1 being an
important downstream Runx2 mediator that preferentially
Fig. 6. Nell-1 affects Runx2
 /  NMCC differentiation. (A) Alp histochemistry on Runx2
 /  NMCCs transduced with AdNell-1 or AdLacZ. Note increased Alp
stainingonday9afterAdNell-1transduction(whole-plateimageatleftandhigher-magnificationimagesatrightofeachpanel).Scalebar:50mm.(B)Relative
quantitation of Alp activity in Runx2
 /  NMCCs transduced with AdNell-1 (red) and AdLacZ (green) or no-treatment (blue) control on days 3, 6, 9, and 12.
 p<.05.(C)Graphdisplayingreal-timeRT-PCRresultsforNell-1,Alp,Opn,andOcnexpressioninRunx2
 / NMCCstransducedwithAdLacZorwithAdNell-1
on days 3, 6, and 9.
  p<.01. (D) Mineralization (ARS) of Runx2
 /  and wild-type NMCCs transducedwith AdNell-1 or AdLacZ on day 27 (whole-plate image
at top and higher-magnification image at bottom of each panel).
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presence of Runx2. The inability of Nell-1 to induce bone
formation in Runx2
 /  NMCCs is of interest. In particular, BMP-2
treatment of Runx2 null cells also failed to induce complete
osteogenic differentiation. Komori and colleagues were able to
induce increased Alp activity and low-level Ocn expression in
Runx2
 /  calvarial cells at pharmacologic dosages of rhBMP-2
above 300ng/mL; however, they noted that those cells did not
form bone and were not considered mature osteoblasts.
(34)
Similarly, long-term culture of E17.5 Runx2
 /  mouse calvarial
cells in osteogenic medium or with BMP-2 also failed to induce
terminal osteoblastic differentiation.
(35) Meanwhile, we demon-
strated that Runx2
 /  NMCCs infected with adenoviral Nell-1
displayed increased Alp transcripts and activity and, to a lesser
degree, Opn transcripts during osteoblastic differentiation in
vitro. Increased Alp or Opn expression demonstrates that
Runx2
 /  NMCCs are responsive to Nell-1 stimulation and that
Nell-1 can induce a certain degree of osteoblastic differentiation
in these cells through Runx2-independent pathways; Runx2,
however, is still absolutely required for complete osteoblastic
differentiation.
Mechanistically, our previous data indicated that Nell-1
induces osteoblastic differentiation inrat andhuman osteoblasts
by activating MAPK pathways as well as promoting Runx2
phosphorylation.
(26) In this study, we evaluated the responsive-
ness of MAPK pathways in NMCCs with different Runx2
genotypes (þ/þ, þ/–, and –/–) and the changes in Runx2
phosphorylation/transactivating activity on rNell-1 stimulation.
Surprisingly, Runx2
 /  NMCCs respond to rNell-1 stimulation as
rapidly as Runx2
þ/  and Runx2
þ/þ NMCCs do with respect to ERK
and JNK pathway activation. However, the intensity and
sustainability of ERK1/2 and JNK1 activation in Runx2
 /  NMCCs
were severely reduced. In addition, Runx2 phosphorylation and
transactivating activity were enhanced on rNell-1 stimulation in
Runx2
þ/þ and Runx2
þ/  NMCCs. In contrast, Runx2
 /  NMCCs
exhibited increased Runx2 phosphorylation and transactivating
activity by rNell-1 stimulation only after introduction of
exogenous Runx2 by transfection. Meanwhile, although rNell-1
stimulation activated ERK1/2 and JNK1 but not p38, the
inhibition of ERK, JNK, or p38 separately reduced Runx2
phosphorylation and mineralization in rNell-1-treated Runx2
þ/þ
NMCCs. These data suggest that Nell-1 promotes osteoblastic
differentiation partially through MAPK pathways that cross-talk
with Runx2 (eg, Nell-1 increases Runx2 phosphorylation and
transactivating activity) and pathways that do not necessarily
cross-talk with Runx2 (eg, Nell-1 increases osteoblastic markers
Alp and Opn expression in Runx2
 /  NMCCs).
Runx2 phosphorylation is thought to be crucial for its
activity.
(27) We postulate a mutually dependent mechanism
between Runx2 and Nell-1 based on the fact that Runx2 directly
regulates Nell-1 transcription
(15) and Nell-1 significantly mod-
ulates Runx2 activity during osteoblastic differentiation. There-
fore, Nell-1 can induce osteoblastic differentiation by at least one
of two mechanisms: (1) enhancing overall Runx2 phosphoryla-
tion and activity (Runx2-dependent) and (2) other effects not
related to modulating Runx2 activity (Runx2-independent).
Conspicuously, ENU-induced Nell-1-deficient mice, while exhibit-
ing similar CCD-like calvarial phenotypes as Runx2
þ/  mice, also
display rib cage vertebral abnormalities not described in Runx2
þ/ 
mice.
(16) This, coupled with our current data demonstrating Nell-
1 induction of Alp and Opn expression in Runx2
 /  NMCCs,
indicates that a subset of Nell-1 effects is not necessarily related
to Runx2 modulation.
Although Runx2 may exert some of its effects mechanistically
through Nell-1 and vice versa, the exact mechanism by which
Nell-1canpromoteosteoblast differentiation througheffects not
related to modulating Runx2 activity is unclear. Structurally,
NELL-1’s N-terminal domain contains a laminin G–like domain
[previously known as an N-terminal thrombospondin 1 (TSP-1)–
like module] that likely interacts with heparan sulfate proteo-
glycans and integrin-related molecules.
(17,26) The EGF-like
domains of rat Nell-1 are phosphorylated by protein kinase C
(PKC) b1,
(36) but it is unknown at this point whether Nell-1
phosphorylation increases or decreases its activity and whether
binding to PKC changes Nell-1’s intracellular distribution or
function or its secretion into the extracellular matrix. In addition,
MAPK may not be the only pathway by which Nell-1 promotes
Runx2 phosphorylation. Given the fact that Nell-1contains TSP-N
and EGF-like repeat domains, other pathways for promoting
Runx2 phosphorylation may involve Nell-1–integrin interactions
involving focal adhesion kinase (FAK) and PKC or calcium-
binding–mediated kinase activation.
(26)
NELL-1 was originally found as a local factor with upregulation
at fusing and fused sutures from UCS patients. Subsequently, we
discovered that NELL-1 transcription is tightly regulated by
Runx2, a key mechanistic convergence point for CS develop-
ment. Interestingly, while syndromic and nonsyndromic CS differ
in extracraniofacial presentation and in the pattern and degree
of suture involvement, the histomorphometric phenotype at the
level of the pathologic closed/closing suture is virtually
indistinguishable.
(37) This implies that even widely disparate
regulatory factors such as fibroblast growth factor receptors
(FGFRs) 1, 2, and 4 and Twist causing distinctly different CS
syndromes nonetheless may converge mechanistically at the
level of the calvaria to affect suture fusion. In fact, altered FGFRs
and Twist activity largely associate with downstream modulation
of Runx2 expression and/or activity—making Runx2 a poten-
tially key molecule of mechanistic convergence for CS.
(38,39)
Overall, Runx2’s activities are etiopathologically involved in
many congenital craniofacial anomalies, including CCD, in
humans caused by Runx2 mutations.
(4,5)
The identification of Nell-1, a secretory molecule, as a key
component of the Runx2-mediated bone-formation network
opens up exciting possibilities for future NELL-1-blocking
therapies to treat CS or other conditions involving undesirable
bone formation (eg, heterotopic ossification). On the other hand,
use of NELL-1 as an osteoinductive molecule may have even
wider applications than anti-NELL-1 therapeutics. Thus far we
have shown comparable Nell-1- versus BMP-induced bone
regeneration in multiple animal models from rat palatal
distraction,
(18) calvarial defect,
(23) and spinal fusion
(40) to sheep
spinal fusion.
(41) More notably, Nell-1, by virtue of being
transcriptionally ‘‘downstream’’ of Runx2, is a more highly
selective osteoinductive molecule in vivo than BMP-2
(20) and is
capable of inducing high-quality bone regeneration from
BMSCs.
(19) The development of more osteoinductive growth
NELL-1 RESCUES CALVARIAL DEFECTS IN RUNX2
þ/  MICE Journal of Bone and Mineral Research 789factors with divergent but complementary bone-formation
pathways can serve to maximize biologic efficiency—which,
in turn, may improve clinical efficacy, lower dose requirements
(and costs), and minimize potential adverse effects of current
osteoinductive therapeutics.
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